Lupin through its subsidiary — Lupin Healthcare (UK) has secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lutio, a generic version of Spiriva (Tiotropium bromide). Lutio has been approved for the treatment of chronic obstructive pulmonary disease (COPD). It is the second inhalation product for the British market from Lupin […]
Lupin said that the UK’ National Institute for Health and Care Excellence (NICE) has recommended Namuscla (mexiletine), an antimyotonic agent, for the approval of its use in the treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM). The Indian pharma company, through its subsidiary — Lupin Healthcare (UK), has agreed to a confidential […]
